133725-73-2

Upstream product

• 1103929-56-1 methyl 6-[(4-chlorophenyl)amino]-6-oxohexanoate 
• 35444-44-1 methyl adipoyl chloride 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 1103929-59-4 6-(4-chlorophenylamino)-6-oxohexanoic acid chloride 
• 1103929-62-9 methyl 5-chloro-2-({6-[(4-chlorophenyl)amino]-6-oxohexanoyl}amino)benzoate 
• 1103926-79-9 5-chloro-2-({6-[(4-chlorophenyl)amino]-6-oxohexanoyl}amino)benzoic acid 

Relevant academic research and scientific papers

Structure-activity relationships of new N-acylanthranilic acid derivatives as plasminogen activator inhibitor-1 inhibitors

Novel anthranilic acid derivatives having substituted N-acyl side chains were designed and synthesized for evaluation as plasminogen activator inhibitor-1 (PAI-1) inhibitors. Compounds with a 4-diphenylmethyl-1-piperazinyl moiety on the acyl side chains in general exhibited potent in vitro PAI-1 inhibitory activity and good pharmacokinetic profiles after oral administration in rats. Compound 16f (TM5275) was identified as a promising candidate for further pharmacological evaluation.

PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR

The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.